请与我们联系上传伦理审查文件。 新型冠状病毒(2019-nCoV)抗原检测试剂盒临床试验

注册号:

Registration number:

ChiCTR2200058260 

最近更新日期:

Date of Last Refreshed on:

2022-12-06 21:03:59 

注册时间:

Date of Registration:

2022-04-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请与我们联系上传伦理审查文件。 新型冠状病毒(2019-nCoV)抗原检测试剂盒临床试验

Public title:

Clinical trials of novel coronavirus (2019-nCoV) antigen detection kit

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型冠状病毒(2019-nCoV)抗原检测试剂盒临床试验

Scientific title:

Clinical trials of novel coronavirus (2019-nCoV) antigen detection kit

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨凯 

研究负责人:

卢水华 

Applicant:

Yang Kai 

Study leader:

Lu Shuihua 

申请注册联系人电话:

Applicant telephone:

+86 755 8845892814

研究负责人电话:

Study leader's
telephone:

+86 18930811818

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yangkaids@163.com

研究负责人电子邮件:

Study leader's E-mail:

lushuihua@shphc.org.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市龙岗区布澜路29号深圳市第三人民医院肺病医学部

研究负责人通讯地址:

广东省深圳市龙岗区布澜路29号深圳市第三人民医院肺病医学部

Applicant address:

29 Bulan Road, Longgang District, Shenzhen, Guangdong

Study leader's address:

29 Bulan Road, Longgang District, Shenzhen, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

深圳市第三人民医院

Applicant's institution:

Shenzhen Third People's Hospital

研究负责人所在单位:

深圳市第三人民医院

Affiliation of the Leader:

Shenzhen Third People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

深圳三院伦审械字[ 2022-021-02]号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

深圳市第三人民医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of Shenzhen Third People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

姚老师

Contact Name of the ethic committee:

Teacher Yao

伦理委员会联系地址:

广东省深圳市龙岗区布澜路29号深圳市第三人民医院

Contact Address of the ethic committee:

29 Bulan Road, Longgang District, Shenzhen, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市第三人民医院

Primary sponsor:

Shenzhen Third People's Hospital

研究实施负责(组长)单位地址:

广东省深圳市龙岗区布澜路29号

Primary sponsor's address:

29 Bulan Road, Longgang District, Shenzhen, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

秦皇岛

Country:

China

Province:

Hebei

City:

Qinhuangdao

单位(医院):

康泰医学系统(秦皇岛)股份有限公司

具体地址:

经济技术开发区秦皇西大街112号

Institution
hospital:

Contec Medical Systems Co., Ltd.

Address:

112 Qinhuang Avenue West, Economic and Technological Development Zone

经费或物资来源:

康泰医学系统(秦皇岛)股份有限公司

Source(s) of funding:

Contec Medical Systems Co., Ltd.

研究疾病:

新型冠状病毒肺炎  

Target disease:

Novel Coronavirus Pneumonia (COVID-19)

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

本临床试验的目的是证明体外诊断试剂能够满足预期使用的要求,并确定产品的适用人群和适应症,具体包括以下两个方面: 1.通过与新型冠状病毒核酸检测结果作为对比,对试验试剂盒检测结果和核酸检测结果进行比较,以评价试剂盒的临床性能; 2.通过比较非专业使用者测试结果和经专业培训的实验室人员检测结果,对非专业使用者进行可用性评价,以证明非专业使用者能够正确理解说明书并正确使用产品进行检测和判读。  

Objectives of Study:

The purpose of this clinical trial is to prove that the in vitro diagnostic reagent can meet the requirements of the intended use, and to determine the suitable population and indications of the product, including the following two aspects: 1. By comparing with the nucleic acid detection results of novel coronavirus, the detection results of test kit and nucleic acid detection results were compared to evaluate the clinical performance of the kit; 2. Conduct usability evaluation for non-professional users by comparing the test results of non-professional users with the test results of professionally-trained laboratory personnel, so as to prove that non-professional users can correctly understand the instructions and correctly use the product for testing and interpretation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.样本采集、保存不符合要求的样本;
2.遭受污染等原因无法进行试验的样本;
3.信息不全无法溯源的样本;
4.其它不符合要求的样本。

Exclusion criteria:

1. Sample collection and storage of unqualified samples;
2. Samples that cannot be tested due to contamination or other reasons;
3. Untraceable samples with incomplete information;
4. Other samples that do not meet requirements.

研究实施时间:

Study execute time:

From 2022-03-31 00:00:00 To 2022-04-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-03-31 00:00:00 To 2022-04-29 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

受试者鼻咽拭子样品的核酸检测

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Nucleic acid detection of nasopharyngeal swab samples of subjects

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

受试者鼻腔拭子样品的抗原检测

Index test:

Antigen detection of nasal swab samples of subjects

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

例数:

Sample size:

250

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

150

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

深圳 

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

深圳市第三人民医院 

单位级别:

三甲 

Institution
hospital:

Shenzhen Third People's Hospital

Level of the institution:

Teritary A

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东省公共卫生临床中心 

单位级别:

三甲 

Institution
hospital:

Shandong Public Health Clinical Center

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

Kappa值

指标类型:

主要指标

Outcome:

Kappa value

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阳性符合率

指标类型:

主要指标

Outcome:

Positive coincidence rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴性符合率

指标类型:

主要指标

Outcome:

Negative coincidence rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总符合率

指标类型:

主要指标

Outcome:

Total coincidence rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

鼻咽拭子

组织:

Sample Name:

Nasopharyngeal swab

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

鼻腔拭子

组织:

Sample Name:

Nasal swab

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计师使用R语言产生随机数,随机数种子分别为1、2和3。

Randomization Procedure (please state who generates the random number sequence and by what method):

Statistician used R language to generate random numbers. The seeds of random numbers are 1, 2 and 3 respectively.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Private

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2022-04-04 00:31:17